|1.||Mitchel, Yale: 7 articles (01/2015 - 02/2009)|
|2.||Gotto, Antonio M: 6 articles (01/2015 - 10/2009)|
|3.||Wagner, John A: 6 articles (11/2014 - 01/2009)|
|4.||Brinton, Eliot A: 5 articles (01/2015 - 10/2009)|
|5.||Barter, Philip: 5 articles (01/2015 - 10/2009)|
|6.||Cannon, Christopher P: 5 articles (01/2015 - 10/2009)|
|7.||Shah, Sukrut: 5 articles (01/2015 - 10/2009)|
|8.||Dansky, Hayes M: 5 articles (11/2014 - 10/2009)|
|9.||Krishna, Rajesh: 5 articles (12/2011 - 01/2009)|
|10.||Davidson, Michael: 4 articles (01/2015 - 10/2009)|
05/01/2008 - "Accordingly, it was recently shown in 2 double-blind, placebo-controlled, randomized, phase I studies with the CETP inhibitor anacetrapib in healthy individuals and in patients with dyslipidemias that the drug increased HDL and reduced LDL, while having no effect on blood pressure."
09/01/2014 - "Anacetrapib: a potential new therapy for dyslipidemia."
12/01/2011 - "Anacetrapib is currently being developed for the oral treatment of dyslipidemia. "
11/01/2011 - "Anacetrapib: a new weapon against dyslipidemia."
01/01/2011 - "Studies evaluating the pharmacology, pharmacokinetics, safety, and efficacy of anacetrapib and dalcetrapib for the treatment of dyslipidemia were included. "
01/01/2015 - "Anacetrapib dose-dependently reduces atherosclerosis, and adds to the anti-atherogenic effects of atorvastatin, which is mainly ascribed to a reduction in non-HDL-C. "
09/01/2009 - "Anacetrapib, a cholesterol ester transfer protein (CETP) inhibitor for the treatment of atherosclerosis."
09/01/2009 - "Dalcetrapib (JTT-705) and anacetrapib, which have not been reported to have the off-target effects of torcetrapib, are currently in Phase III. They are expected to reveal whether CETP inhibition is beneficial for atherosclerosis-related diseases."
01/01/2015 - "We evaluated the effects of a broad dose range of anacetrapib on atherosclerosis and HDL function, and examined possible additive/synergistic effects of anacetrapib on top of atorvastatin in APOE*3Leiden.CETP mice. "
01/01/2015 - "Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin."
|3.||Coronary Disease (Coronary Heart Disease)
12/16/2010 - "We conducted a randomized, double-blind, placebo-controlled trial to assess the efficacy and safety profile of anacetrapib in patients with coronary heart disease or at high risk for coronary heart disease. "
01/01/2010 - "Add-on therapy with anacetrapib is currently being evaluated in a 76-week phase III trial in patients with coronary heart disease (CHD) or CHD risk-equivalent disease in the US, Germany, Spain, and Austria. "
10/01/2009 - "Determining the EFficacy and Tolerability of CETP INhibition with AnacEtrapib (DEFINE) is a randomized, double-blind, placebo-controlled trial to assess the efficacy and safety profile of anacetrapib in patients with coronary heart disease (CHD) or CHD risk equivalents (clinical trials.gov NCT00685776). "
12/16/2010 - "Safety of anacetrapib in patients with or at high risk for coronary heart disease."
08/01/2012 - "In the Phase III DEFINE trial conducted in patients with or at high risk for coronary heart disease, anacetrapib reduced LDL cholesterol levels by 39.8% after 24 weeks compared with placebo and demonstrated an acceptable safety profile through 76 weeks of treatment (the primary end points). "
|4.||Cardiovascular Diseases (Cardiovascular Disease)
01/01/2015 - "The clinical impact of the lipid-modifying effects of anacetrapib is being evaluated in the cardiovascular disease outcomes trial, Randomized EValuation of the Effects of Anacetrapib though Lipid-modification (REVEAL)."
10/01/2013 - "Anacetrapib (MK-0859) is currently in phase III trials for the treatment of elevated cholesterol levels and prevention of cardiovascular disease. "
08/01/2011 - "Results from ongoing clinical outcomes studies with anacetrapib and dalcetrapib will clarify the relevance of CETP inhibition versus modulation towards HDL remodelling in the treatment of cardiovascular diseases."
01/01/2011 - "Results of future trials are much anticipated, as these will clarify the role of anacetrapib and dalcetrapib in reduction of cardiovascular disease."
09/01/2014 - "Anacetrapib is a cholesteryl ester transfer protein (CETP) inhibitor currently in Phase III of development as a treatment for those with dyslipidemia and the risk of cardiovascular disease. "
01/01/2012 - "However, anacetrapib does not appear to exhibit these effects and is being developed as a selective inhibitor of CETP to be orally administered for the treatment of primary hypercholesterolemia and mixed hyperlipidemia. "
11/01/2011 - "Anacetrapib is a cholesteryl-ester-transfer-protein (CETP) inhibitor, a new class of experimental drugs in the treatment of primary hypercholesterolemia and dyslipidaemia associated with the metabolic syndrome. "
02/01/2009 - "A total of 589 patients with primary hypercholesterolemia or mixed hyperlipidemia (53.8% of the study population had low HDL-C) were randomized equally to one of 10 groups: 5 groups received background statin therapy of atorvastatin 20 mg and 5 did not, and each of these was randomized to placebo, anacetrapib 10, 40, 150, and 300 mg once daily for 8 weeks. "
03/01/2010 - "Anacetrapib is a novel cholesteryl ester transfer protein inhibitor being developed for the treatment of primary hypercholesterolemia and mixed dyslipidemia. "
10/01/2011 - "Efficacy and safety after cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib (MK-0859) in patients with primary hypercholesterolemia or mixed hyperlipidemia."
|4.||Cholesterol Ester Transfer Proteins
|10.||Cytochrome P-450 CYP3A